{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T16:55:24Z","timestamp":1790355324332,"version":"4.1.0"},"reference-count":62,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T00:00:00Z","timestamp":1725494400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"NIH","award":["1F30AI181515-01"],"award-info":[{"award-number":["1F30AI181515-01"]}]},{"name":"NIH","award":["R01 GM135919"],"award-info":[{"award-number":["R01 GM135919"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Enterovirus-D68 (EV68) has emerged as a global health concern over the last decade with severe symptomatic infections resulting in long-lasting neurological deficits and death. Unfortunately, there are currently no FDA-approved antiviral drugs for EV68 or any other non-polio enterovirus. One particularly attractive class of potential drugs are small molecules inhibitors, which can target the conserved active site of EV68-3C protease. For other viral proteases, we have demonstrated that the emergence of drug resistance can be minimized by designing inhibitors that leverage the evolutionary constraints of substrate specificity. However, the structural characterization of EV68-3C protease bound to its substrates has been lacking. Here, we have determined the substrate specificity of EV68-3C protease through molecular modeling, molecular dynamics (MD) simulations, and co-crystal structures. Molecular models enabled us to successfully characterize the conserved hydrogen-bond networks between EV68-3C protease and the peptides corresponding to the viral cleavage sites. In addition, co-crystal structures we determined have revealed substrate-induced conformational changes of the protease which involved new interactions, primarily surrounding the S1 pocket. We calculated the substrate envelope, the three-dimensional consensus volume occupied by the substrates within the active site. With the elucidation of the EV68-3C protease substrate envelope, we evaluated how 3C protease inhibitors, AG7088 and SG-85, fit within the active site to predict potential resistance mutations.<\/jats:p>","DOI":"10.3390\/v16091419","type":"journal-article","created":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T04:15:11Z","timestamp":1725509711000},"page":"1419","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Elucidating the Substrate Envelope of Enterovirus 68-3C Protease: Structural Basis of Specificity and Potential Resistance"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3186-4760","authenticated-orcid":false,"given":"Vincent N.","family":"Azzolino","sequence":"first","affiliation":[{"name":"Department of Biochemistry and Molecular Biotechnology, University of Massachusetts Chan Medical School, Worcester, MA 01605, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ala M.","family":"Shaqra","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biotechnology, University of Massachusetts Chan Medical School, Worcester, MA 01605, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akbar","family":"Ali","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biotechnology, University of Massachusetts Chan Medical School, Worcester, MA 01605, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5036-676X","authenticated-orcid":false,"given":"Nese","family":"Kurt Yilmaz","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biotechnology, University of Massachusetts Chan Medical School, Worcester, MA 01605, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2270-6613","authenticated-orcid":false,"given":"Celia A.","family":"Schiffer","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biotechnology, University of Massachusetts Chan Medical School, Worcester, MA 01605, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,9,5]]},"reference":[{"key":"ref_1","unstructured":"Howley, P.M., and Knipe, D.M. (2013). Enteroviruses: Polioviruses, Coxsackieviruses, Echoviruses, and Newer Enteroviruses, Fields Virology Lippincott Williams & Wilkins. [6th ed.]."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1097\/QCO.0000000000000187","article-title":"The epidemiology of non-polio enteroviruses: Recent advances and outstanding questions","volume":"28","author":"Parker","year":"2015","journal-title":"Curr. Opin. Infect. Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1002\/jmv.24410","article-title":"2014 outbreak of enterovirus D68 in North America","volume":"88","author":"Messacar","year":"2016","journal-title":"J. Med. Virol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1182\/blood-2014-12-616516","article-title":"Clinical disease due to enterovirus D68 in adult hematologic malignancy patients and hematopoietic cell transplant recipients","volume":"125","author":"Waghmare","year":"2015","journal-title":"Blood"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/s41579-018-0005-4","article-title":"The life cycle of non-polio enteroviruses and how to target it","volume":"16","author":"Baggen","year":"2018","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.chom.2016.09.013","article-title":"ICAM-5\/Telencephalin Is a Functional Entry Receptor for Enterovirus D68","volume":"20","author":"Wei","year":"2016","journal-title":"Cell Host Microbe"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"245","DOI":"10.3174\/ajnr.A4188","article-title":"MRI findings in children with acute flaccid paralysis and cranial nerve dysfunction occurring during the 2014 enterovirus D68 outbreak","volume":"36","author":"Maloney","year":"2015","journal-title":"AJNR Am. J. Neuroradiol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"573","DOI":"10.3201\/eid2503.170897","article-title":"Acute Flaccid Myelitis Associated with Enterovirus D68 in Children, Argentina, 2016","volume":"25","author":"Carballo","year":"2019","journal-title":"Emerg. Infect. Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2807\/1560-7917.ES.2018.23.3.17-00310","article-title":"The association between acute flaccid myelitis (AFM) and Enterovirus D68 (EV-D68)\u2014What is the evidence for causation?","volume":"23","author":"Dyda","year":"2018","journal-title":"Eurosurveillance"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/S0140-6736(20)32723-9","article-title":"Acute flaccid myelitis: Cause, diagnosis, and management","volume":"397","author":"Murphy","year":"2021","journal-title":"Lancet"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1002\/ana.24730","article-title":"Acute flaccid myelitis: A clinical review of US cases 2012\u20132015","volume":"80","author":"Messacar","year":"2016","journal-title":"Ann. Neurol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.pediatrneurol.2019.08.009","article-title":"Unmet Needs in the Evaluation, Treatment, and Recovery for 167 Children Affected by Acute Flaccid Myelitis Reported by Parents through Social Media","volume":"102","author":"Bove","year":"2020","journal-title":"Pediatr. Neurol."},{"key":"ref_13","first-page":"245","article-title":"Acute flaccid myelitis: Rehabilitation challenges and outcomes in a pediatric cohort","volume":"12","author":"Melicosta","year":"2019","journal-title":"J. Pediatr. Rehabil. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1212\/WNL.0000000000004081","article-title":"Outcomes of Colorado children with acute flaccid myelitis at 1 year","volume":"89","author":"Martin","year":"2017","journal-title":"Neurology"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Brown, D.M., Zhang, Y., and Scheuermann, R.H. (2020). Epidemiology and Sequence-Based Evolutionary Analysis of Circulating Non-Polio Enteroviruses. Microorganisms, 8.","DOI":"10.3390\/microorganisms8121856"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.3201\/eid2208.151949","article-title":"Enterovirus D68 Infection in Children with Acute Flaccid Myelitis, Colorado, USA, 2014","volume":"22","author":"Aliabadi","year":"2016","journal-title":"Emerg. Infect. Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"4339","DOI":"10.1128\/JVI.01123-12","article-title":"3C protease of enterovirus 68: Structure-based design of Michael acceptor inhibitors and their broad-spectrum antiviral effects against picornaviruses","volume":"87","author":"Tan","year":"2013","journal-title":"J. Virol."},{"key":"ref_18","unstructured":"Fields, B.N., Knipe, D.M., and Howley, P.M. (2013). Fields Virology, Virology; Wolters Kluwer Health\/Lippincott Williams & Wilkins. [6th ed.]."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1002\/med.20125","article-title":"Selective inhibitors of picornavirus replication","volume":"28","author":"Vliegen","year":"2008","journal-title":"Med. Res. Rev."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/d41573-021-00202-8","article-title":"A tale of two antiviral targets\u2014And the COVID-19 drugs that bind them","volume":"21","author":"Cully","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"10319","DOI":"10.1128\/JVI.00787-11","article-title":"Enterovirus 71 and coxsackievirus A16 3C proteases: Binding to rupintrivir and their substrates and anti-hand, foot, and mouth disease virus drug design","volume":"85","author":"Lu","year":"2011","journal-title":"J. Virol."},{"key":"ref_22","first-page":"1333","article-title":"Combating susceptibility to drug resistance: Lessons from HIV-1 protease","volume":"11","author":"King","year":"2004","journal-title":"Chem. Biol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3556","DOI":"10.1038\/s41467-022-31210-w","article-title":"Defining the substrate envelope of SARS-CoV-2 main protease to predict and avoid drug resistance","volume":"13","author":"Shaqra","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Romano, K.P., Ali, A., Aydin, C., Soumana, D., Ozen, A., Deveau, L.M., Silver, C., Cao, H., Newton, A., and Petropoulos, C.J. (2012). The molecular basis of drug resistance against hepatitis C virus NS3\/4A protease inhibitors. PLoS Pathog., 8.","DOI":"10.1371\/journal.ppat.1002832"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"20986","DOI":"10.1073\/pnas.1006370107","article-title":"Drug resistance against HCV NS3\/4A inhibitors is defined by the balance of substrate recognition versus inhibitor binding","volume":"107","author":"Romano","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S0969-2126(02)00720-7","article-title":"Substrate shape determines specificity of recognition for HIV-1 protease: Analysis of crystal structures of six substrate complexes","volume":"10","author":"Nalivaika","year":"2002","journal-title":"Structure"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.3390\/v2112509","article-title":"Molecular Basis for Drug Resistance in HIV-1 Protease","volume":"2","author":"Ali","year":"2010","journal-title":"Viruses"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/j.chembiol.2013.07.014","article-title":"Substrate envelope-designed potent HIV-1 protease inhibitors to avoid drug resistance","volume":"20","author":"Nalam","year":"2013","journal-title":"Chem. Biol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3238","DOI":"10.1021\/acs.chemrev.0c00648","article-title":"Drug Design Strategies to Avoid Resistance in Direct-Acting Antivirals and Beyond","volume":"121","author":"Matthew","year":"2021","journal-title":"Chem. Rev."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1080\/10409238.2019.1568962","article-title":"Resistance outside the substrate envelope: Hepatitis C NS3\/4A protease inhibitors","volume":"54","author":"Ozen","year":"2019","journal-title":"Crit. Rev. Biochem. Mol. Biol."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Matthew, A.N., Zephyr, J., Nageswara Rao, D., Henes, M., Kamran, W., Kosovrasti, K., Hedger, A.K., Lockbaum, G.J., Timm, J., and Ali, A. (2020). Avoiding Drug Resistance by Substrate Envelope-Guided Design: Toward Potent and Robust HCV NS3\/4A Protease Inhibitors. mBio, 11.","DOI":"10.1128\/mBio.00172-20"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1128\/AAC.49.2.619-626.2005","article-title":"Conservation of amino acids in human rhinovirus 3C protease correlates with broad-spectrum antiviral activity of rupintrivir, a novel human rhinovirus 3C protease inhibitor","volume":"49","author":"Binford","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"11000","DOI":"10.1073\/pnas.96.20.11000","article-title":"Structure-assisted design of mechanism-based irreversible inhibitors of human rhinovirus 3C protease with potent antiviral activity against multiple rhinovirus serotypes","volume":"96","author":"Matthews","year":"1999","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1128\/AAC.43.10.2444","article-title":"In vitro antiviral activity of AG7088, a potent inhibitor of human rhinovirus 3C protease","volume":"43","author":"Patick","year":"1999","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1128\/AAC.49.6.2267-2275.2005","article-title":"In vitro antiviral activity and single-dose pharmacokinetics in humans of a novel, orally bioavailable inhibitor of human rhinovirus 3C protease","volume":"49","author":"Patick","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1021\/jm980537b","article-title":"Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 3. Structure-activity studies of ketomethylene-containing peptidomimetics","volume":"42","author":"Dragovich","year":"1999","journal-title":"J. Med. Chem."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"4572","DOI":"10.1021\/jm030166l","article-title":"Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 8. Pharmacological optimization of orally bioavailable 2-pyridone-containing peptidomimetics","volume":"46","author":"Dragovich","year":"2003","journal-title":"J. Med. Chem."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1021\/jm9805384","article-title":"Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 4. Incorporation of P1 lactam moieties as L-glutamine replacements","volume":"42","author":"Dragovich","year":"1999","journal-title":"J. Med. Chem."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1021\/jm980068d","article-title":"Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 1. Michael acceptor structure-activity studies","volume":"41","author":"Dragovich","year":"1998","journal-title":"J. Med. Chem."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1021\/jm9800696","article-title":"Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 2. Peptide structure-activity studies","volume":"41","author":"Dragovich","year":"1998","journal-title":"J. Med. Chem."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/S0968-0896(99)00005-X","article-title":"Solid-phase synthesis of irreversible human rhinovirus 3C protease inhibitors. Part 1: Optimization of tripeptides incorporating N-terminal amides","volume":"7","author":"Dragovich","year":"1999","journal-title":"Bioorg. Med. Chem."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2925","DOI":"10.1021\/acs.biochem.1c00414","article-title":"Pan-3C Protease Inhibitor Rupintrivir Binds SARS-CoV-2 Main Protease in a Unique Binding Mode","volume":"60","author":"Lockbaum","year":"2021","journal-title":"Biochemistry"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"5368","DOI":"10.1128\/JVI.02531-09","article-title":"Evaluating the substrate-envelope hypothesis: Structural analysis of novel HIV-1 protease inhibitors designed to be robust against drug resistance","volume":"84","author":"Nalam","year":"2010","journal-title":"J. Virol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1021\/acsinfecdis.8b00336","article-title":"Structural Adaptation of Darunavir Analogues against Primary Mutations in HIV-1 Protease","volume":"5","author":"Lockbaum","year":"2019","journal-title":"ACS Infect. Dis."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1021\/acschembio.9b00370","article-title":"Picomolar to Micromolar: Elucidating the Role of Distal Mutations in HIV-1 Protease in Conferring Drug Resistance","volume":"14","author":"Henes","year":"2019","journal-title":"ACS Chem. Biol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1021\/acschembio.0c00975","article-title":"Inhibiting HTLV-1 Protease: A Viable Antiviral Target","volume":"16","author":"Lockbaum","year":"2021","journal-title":"ACS Chem. Biol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"4366","DOI":"10.1128\/AAC.00905-07","article-title":"In vitro resistance study of rupintrivir, a novel inhibitor of human rhinovirus 3C protease","volume":"51","author":"Binford","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.jmb.2011.03.053","article-title":"Dynamics of preferential substrate recognition in HIV-1 protease: Redefining the substrate envelope","volume":"410","author":"Ozen","year":"2011","journal-title":"J. Mol. Biol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"5693","DOI":"10.1021\/ct400603p","article-title":"Improving the Resistance Profile of Hepatitis C NS3\/4A Inhibitors: Dynamic Substrate Envelope Guided Design","volume":"9","author":"Ozen","year":"2013","journal-title":"J. Chem. Theory Comput."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1107\/S0907444909047337","article-title":"Xds","volume":"66","author":"Kabsch","year":"2010","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1107\/S0021889807021206","article-title":"Phaser crystallographic software","volume":"40","author":"McCoy","year":"2007","journal-title":"J. Appl. Crystallogr."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1107\/S0907444904019158","article-title":"Coot: Model-building tools for molecular graphics","volume":"60","author":"Emsley","year":"2004","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1107\/S0907444910007493","article-title":"Features and development of Coot","volume":"66","author":"Emsley","year":"2010","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1107\/S0907444909052925","article-title":"PHENIX: A comprehensive Python-based system for macromolecular structure solution","volume":"66","author":"Adams","year":"2010","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1038\/355472a0","article-title":"Free R value: A novel statistical quantity for assessing the accuracy of crystal structures","volume":"355","author":"Brunger","year":"1992","journal-title":"Nature"},{"key":"ref_56","unstructured":"Schr\u00f6dinger (2019). Schr\u00f6dinger Release 2019\u20132, Schr\u00f6dinger LLC."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1021\/acs.jctc.8b00097","article-title":"Hydration Structure and Dynamics of Inhibitor-Bound HIV-1 Protease","volume":"14","author":"Leidner","year":"2018","journal-title":"J. Chem. Theory Comput."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S0022-2836(02)00470-9","article-title":"On the role of the crystal environment in determining protein side-chain conformations","volume":"320","author":"Jacobson","year":"2002","journal-title":"J. Mol. Biol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1021\/ct100578z","article-title":"PROPKA3: Consistent Treatment of Internal and Surface Residues in Empirical pKa Predictions","volume":"7","author":"Olsson","year":"2011","journal-title":"J. Chem. Theory Comput."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1021\/acs.jctc.5b00864","article-title":"OPLS3: A Force Field Providing Broad Coverage of Drug-like Small Molecules and Proteins","volume":"12","author":"Harder","year":"2016","journal-title":"J. Chem. Theory Comput."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1021\/acs.jctc.0c01244","article-title":"Deciphering Complex Mechanisms of Resistance and Loss of Potency through Coupled Molecular Dynamics and Machine Learning","volume":"17","author":"Leidner","year":"2021","journal-title":"J. Chem. Theory Comput."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1021\/cb400100g","article-title":"Evaluating the role of macrocycles in the susceptibility of hepatitis C virus NS3\/4A protease inhibitors to drug resistance","volume":"8","author":"Ali","year":"2013","journal-title":"ACS Chem. Biol."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/16\/9\/1419\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:48:54Z","timestamp":1760111334000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/16\/9\/1419"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,5]]},"references-count":62,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,9]]}},"alternative-id":["v16091419"],"URL":"https:\/\/doi.org\/10.3390\/v16091419","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,5]]}}}